8-Hydroxyquinolines are bactericidal against Mycobacterium tuberculosis.


Journal

Drug development research
ISSN: 1098-2299
Titre abrégé: Drug Dev Res
Pays: United States
ID NLM: 8204468

Informations de publication

Date de publication:
08 2019
Historique:
received: 10 12 2018
revised: 21 02 2019
accepted: 05 03 2019
pubmed: 21 3 2019
medline: 28 1 2020
entrez: 21 3 2019
Statut: ppublish

Résumé

There is an urgent need for new treatments effective against Mycobacterium tuberculosis, the causative agent of tuberculosis. The 8-hydroxyquinoline series is a privileged scaffold with anticancer, antifungal, and antibacterial activities. We conducted a structure-activity relationship study of the series regarding its antitubercular activity using 26 analogs. The 8-hydroxyquinolines showed good activity against M. tuberculosis, with minimum inhibitory concentrations (MIC90) of <5 μM for some analogs. Small substitutions at C5 resulted in the most potent activity. Substitutions at C2 generally decreased potency, although a sub-family of 2-styryl-substituted analogs retained activity. Representative compounds demonstrated bactericidal activity against replicating M. tuberculosis with >4 log kill at 10× MIC over 14 days. The majority of the compounds demonstrated cytotoxicity (IC

Identifiants

pubmed: 30893501
doi: 10.1002/ddr.21531
pmc: PMC6767403
doi:

Substances chimiques

Antitubercular Agents 0
Hydroxyquinolines 0
Oxyquinoline 5UTX5635HP

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

566-572

Informations de copyright

© 2019 The Authors. Drug Development Research published by Wiley Periodicals, Inc.

Références

Bioorg Med Chem Lett. 2014 Nov 1;24(21):5076-80
pubmed: 25264073
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5765-76
pubmed: 27431227
Bioorg Med Chem Lett. 2014 Jan 1;24(1):367-70
pubmed: 24269165
Chemistry. 2016 Jun 27;22(27):9181-9
pubmed: 27245927
Bioorg Med Chem. 2006 May 15;14(10):3592-8
pubmed: 16458522
EXCLI J. 2018 Aug 23;17:840-846
pubmed: 30233282
Nature. 1951 Jul 7;168(4262):29
pubmed: 14852936
Life Sci. 1999;64(9):813-25
pubmed: 10075114
Bioorg Med Chem. 2015 Aug 1;23(15):4188-4196
pubmed: 26183541
Biochem Biophys Rep. 2016 Mar 24;6:135-141
pubmed: 29214226
J Pharm Sci. 1975 Sep;64(9):1563-6
pubmed: 810572
Methods Mol Biol. 2015;1285:269-79
pubmed: 25779322
PLoS One. 2015 Nov 23;10(11):e0142678
pubmed: 26599982
J Appl Microbiol. 2000 May;88(5):784-90
pubmed: 10792538
Bioorg Med Chem. 2012 Dec 15;20(24):6960-8
pubmed: 23159041
Antimicrob Agents Chemother. 2007 Mar;51(3):1105-6
pubmed: 17178795
PLoS One. 2013 Apr 04;8(4):e60531
pubmed: 23593234
Mol Pharm. 2014 Apr 7;11(4):1151-63
pubmed: 24592930
PLoS One. 2010 Mar 23;5(3):e9823
pubmed: 20352111
Org Biomol Chem. 2012 Apr 21;10(15):2979-92
pubmed: 22391578
ChemMedChem. 2015 Jul;10(7):1157-62
pubmed: 25982664
ACS Med Chem Lett. 2013 Jul 1;4(8):
pubmed: 24376907
J Med Chem. 2013 Jan 24;56(2):521-33
pubmed: 23252745
Eur J Med Chem. 2015 Nov 13;105:145-55
pubmed: 26491978
Drug Des Devel Ther. 2013 Oct 04;7:1157-78
pubmed: 24115839
Ann Inst Pasteur (Paris). 1952 Aug;83(2):275-6
pubmed: 12986381
PLoS One. 2019 Jan 16;14(1):e0205479
pubmed: 30650074
Medchemcomm. 2016 Jul 27;8(4):720-724
pubmed: 30108790
Bioorg Med Chem. 2016 Apr 15;24(8):1889-97
pubmed: 26979485
Eur J Med Chem. 2009 Feb;44(2):558-67
pubmed: 18485536
Drug Dev Res. 2019 Aug;80(5):566-572
pubmed: 30893501
J Antimicrob Chemother. 2010 Jul;65(7):1424-7
pubmed: 20435781
Bioorg Med Chem. 2010 Jan 1;18(1):124-33
pubmed: 19944612
Tuberculosis (Edinb). 2009 Sep;89(5):334-53
pubmed: 19758845
BMC Res Notes. 2018 Oct 1;11(1):685
pubmed: 30285840

Auteurs

Joshua O Odingo (JO)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Julie V Early (JV)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Jake Smith (J)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

James Johnson (J)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Mai A Bailey (MA)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Megan Files (M)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Junitta Guzman (J)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Juliane Ollinger (J)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Aaron Korkegian (A)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Anuradha Kumar (A)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Yulia Ovechkina (Y)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Tanya Parish (T)

TB Discovery Research, Infectious Disease Research Institute, Seattle, Washington.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH